Skip to main content
Erschienen in: Clinical and Translational Oncology 12/2018

23.05.2018 | Research Article

Does NEMO/IKKγ protein have a role in determining prognostic significance in uveal melanoma?

verfasst von: M. K. Singh, N. Pushker, R. Meel, K. Chodsol, S. Sen, S. Bakhshi, L. Singh, S. Kashyap

Erschienen in: Clinical and Translational Oncology | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Uveal melanoma, although a rare form of cancer, is the most common primary malignancy of the eye in adults. Nuclear factor-κB (NF-κB) is a transcription factor that transactivates genes involved in the regulation of cell growth, apoptosis, angiogenesis, and metastasis, but the molecular mechanisms that negatively regulate NF-κB activation are not fully understood. NF-κB can also be activated by DNA damage pathway through NEMO protein. Therefore, the objective of this study is to elucidate the role of NEMO/IKKγ protein in uveal melanoma patients.

Methods

Seventy-five formalin-fixed paraffin-embedded prospective tissues of uveal melanoma were included in the present study. These cases were reviewed and investigated for the expression of NEMO/IKKγ protein by immunohistochemistry and validated by western blotting along with the qRT-PCR for mRNA expression. Expression levels were correlated with the clinicopathological parameters and patients’ outcome.

Results

Immunohistochemistry showed cytoplasmic expression of NEMO/IKKγ expression in only 22 out of 75 (29.33%) cases. This result was confirmed by western blotting, and correlated well with the immunohistochemical expression of NEMO/IKKγ protein (48 kDa). In addition, downregulation of this gene was found in 87.93% of the cases when compared with the normal tissues. On statistical analysis, loss of NEMO/IKKγ protein was correlated with neovascularization, high mitotic count, and presence of vascular loop (p < 0.05). There was less overall survival rate with low expression of NEMO/IKKγ protein in patients with uveal melanoma.

Conclusion

This was the first study suggesting the relevant role of NEMO/IKKγ protein, and highlights the prognostic significance with outcome in uveal melanoma patients. This protein might be used as a screening biomarker in these patients after large-scale validation and translational studies.
Literatur
1.
Zurück zum Zitat Hu DN, Yu GP, McCormick SA, Schneider S, Finger PT. Population-based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol. 2005;140:612–7.CrossRef Hu DN, Yu GP, McCormick SA, Schneider S, Finger PT. Population-based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol. 2005;140:612–7.CrossRef
2.
Zurück zum Zitat Kashyap Seema, Venkatesh Pradeep, Sen Seema, Khanduja Sumeet, Shrey Dinesh, Garg Sana Tinwala Satpal. Clinicopathologic characteristics of choroidal melanoma in a North Indian population: analysis of 10-year data. Int Ophthalmol. 2014;34:235–9.CrossRef Kashyap Seema, Venkatesh Pradeep, Sen Seema, Khanduja Sumeet, Shrey Dinesh, Garg Sana Tinwala Satpal. Clinicopathologic characteristics of choroidal melanoma in a North Indian population: analysis of 10-year data. Int Ophthalmol. 2014;34:235–9.CrossRef
3.
Zurück zum Zitat Shields CL, Kaliki S, Furuta M, Mashayekhi A, Shields JA. Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina. 2012;32:1363–72.CrossRef Shields CL, Kaliki S, Furuta M, Mashayekhi A, Shields JA. Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina. 2012;32:1363–72.CrossRef
4.
Zurück zum Zitat McLaughlin CC, Wu XC, Jemal A, Martin HJ, Roche LM, Chen VW. Incidence of noncutaneous melanomas in the U.S. Cancer. 2005;103:1000–7.CrossRef McLaughlin CC, Wu XC, Jemal A, Martin HJ, Roche LM, Chen VW. Incidence of noncutaneous melanomas in the U.S. Cancer. 2005;103:1000–7.CrossRef
5.
Zurück zum Zitat Damato EM, Damato BE. Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2,384 patients. Ophthalmology. 2012;119:1582–9.CrossRef Damato EM, Damato BE. Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2,384 patients. Ophthalmology. 2012;119:1582–9.CrossRef
6.
Zurück zum Zitat Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V Twelve-year mortality rates and prognostic factors: COMS report No 28. Arch Ophthalmol. 2006;124:1684–93.CrossRef Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V Twelve-year mortality rates and prognostic factors: COMS report No 28. Arch Ophthalmol. 2006;124:1684–93.CrossRef
7.
Zurück zum Zitat Rajpal S, Moore R, Karakousis CP. Survival in metastatic ocular melanoma. Cancer. 1983;52:334–6.CrossRef Rajpal S, Moore R, Karakousis CP. Survival in metastatic ocular melanoma. Cancer. 1983;52:334–6.CrossRef
8.
Zurück zum Zitat Bedikian AY. Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin. 2006;46:151–66.CrossRef Bedikian AY. Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin. 2006;46:151–66.CrossRef
9.
Zurück zum Zitat Brasiuniene B, Sokolovas V, Brasiunas V, Barakauskiene A, Strupas K. Combined treatment of uveal melanoma liver metastases. Eur J Med Res. 2011;16:71–5.CrossRef Brasiuniene B, Sokolovas V, Brasiunas V, Barakauskiene A, Strupas K. Combined treatment of uveal melanoma liver metastases. Eur J Med Res. 2011;16:71–5.CrossRef
10.
Zurück zum Zitat Aigelsreiter A, Haybaeck J, Schauer S, Kiesslich T, Bettermann K, Griessbacher A, Stojakovic T, Bauernhofer T, Samonigg H, Kornprat P, Lackner C, Pichler M. NEMO expression in human hepatocellular carcinoma and its association with clinical outcome. Hum Pathol. 2012;43:1012–9.CrossRef Aigelsreiter A, Haybaeck J, Schauer S, Kiesslich T, Bettermann K, Griessbacher A, Stojakovic T, Bauernhofer T, Samonigg H, Kornprat P, Lackner C, Pichler M. NEMO expression in human hepatocellular carcinoma and its association with clinical outcome. Hum Pathol. 2012;43:1012–9.CrossRef
11.
Zurück zum Zitat Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev. 2004;18:2195–224.CrossRef Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev. 2004;18:2195–224.CrossRef
12.
Zurück zum Zitat Chen F, Beezhold K, Castranova V. Tumor promoting or tumor suppressing of NF-kappa B, a matter of cell context dependency. Int Rev Immunol. 2008;27:183–204.CrossRef Chen F, Beezhold K, Castranova V. Tumor promoting or tumor suppressing of NF-kappa B, a matter of cell context dependency. Int Rev Immunol. 2008;27:183–204.CrossRef
13.
Zurück zum Zitat Rothwarf DM, Zandi E, Natoli G, Karin M. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature. 1998;395:297–300.CrossRef Rothwarf DM, Zandi E, Natoli G, Karin M. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature. 1998;395:297–300.CrossRef
14.
Zurück zum Zitat Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, Roskams T, Trautwein C, Pasparakis M. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell. 2007;11:119–32.CrossRef Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, Roskams T, Trautwein C, Pasparakis M. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell. 2007;11:119–32.CrossRef
15.
Zurück zum Zitat Aradhya S, Woffendin H, Jakins T, Bardaro T, Esposito T, Smahi A, Shaw C, Levy M, Munnich A, D’Urso M, Lewis RA, Kenwrick S, Nelson DL. A recurrent deletion in the ubiquitously expressed NEMO (IKK-gamma) gene accounts for the vast majority of incontinentia pigmenti mutations. Hum Mol Genet. 2001;10(19):2171–9.CrossRef Aradhya S, Woffendin H, Jakins T, Bardaro T, Esposito T, Smahi A, Shaw C, Levy M, Munnich A, D’Urso M, Lewis RA, Kenwrick S, Nelson DL. A recurrent deletion in the ubiquitously expressed NEMO (IKK-gamma) gene accounts for the vast majority of incontinentia pigmenti mutations. Hum Mol Genet. 2001;10(19):2171–9.CrossRef
16.
Zurück zum Zitat Zonana J, Elder ME, Schneider LC, Orlow SJ, Moss C, Golabi M, Shapira SK, Farndon PA, Wara DW, Emmal SA, Ferguson BM. A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). Am J Hum Genet. 2000;67:1555–62.CrossRef Zonana J, Elder ME, Schneider LC, Orlow SJ, Moss C, Golabi M, Shapira SK, Farndon PA, Wara DW, Emmal SA, Ferguson BM. A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). Am J Hum Genet. 2000;67:1555–62.CrossRef
17.
Zurück zum Zitat Nogai H, Wenzel SS, Hailfinger S, Grau M, Kaergel E, Seitz V, Wollert-Wulf B, Pfeifer M, Wolf A, Frick M, Dietze K, Madle H, Tzankov A, Hummel M, Dörken B, Scheidereit C, Janz M, Lenz P, Thome M, Lenz G. IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL. Blood. 2013;122:2242–50.CrossRef Nogai H, Wenzel SS, Hailfinger S, Grau M, Kaergel E, Seitz V, Wollert-Wulf B, Pfeifer M, Wolf A, Frick M, Dietze K, Madle H, Tzankov A, Hummel M, Dörken B, Scheidereit C, Janz M, Lenz P, Thome M, Lenz G. IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL. Blood. 2013;122:2242–50.CrossRef
18.
Zurück zum Zitat Madge LA, May MJ. Inhibiting proinflammatory NF-kappaB signalling using cell-penetrating NEMO binding domain peptides. Methods Mol Biol. 2009;512:209–32.CrossRef Madge LA, May MJ. Inhibiting proinflammatory NF-kappaB signalling using cell-penetrating NEMO binding domain peptides. Methods Mol Biol. 2009;512:209–32.CrossRef
19.
Zurück zum Zitat McLean IW, Foster WD, Zimmerman LE, Gamel JW. Modifications of Callender’s classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol. 1983;96:502–9.CrossRef McLean IW, Foster WD, Zimmerman LE, Gamel JW. Modifications of Callender’s classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol. 1983;96:502–9.CrossRef
20.
Zurück zum Zitat The AJCC Ophthalmic Oncology Task Force. International Validation of the American Joint Committee on Cancer’s 7th edition classification of uveal melanoma. JAMA Ophthalmol. 2015;133:376–83.CrossRef The AJCC Ophthalmic Oncology Task Force. International Validation of the American Joint Committee on Cancer’s 7th edition classification of uveal melanoma. JAMA Ophthalmol. 2015;133:376–83.CrossRef
21.
Zurück zum Zitat Griewank KG, Murali R. Pathology and genetics of uveal melanoma. Pathology. 2013;45:18–27.CrossRef Griewank KG, Murali R. Pathology and genetics of uveal melanoma. Pathology. 2013;45:18–27.CrossRef
22.
Zurück zum Zitat Augsburger JJ, Correa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol. 2009;148:119–27.CrossRef Augsburger JJ, Correa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol. 2009;148:119–27.CrossRef
23.
Zurück zum Zitat Kim IK, Lane AM, Gragoudas ES. Survival in patients with presymptomatic diagnosis of metastatic uveal melanoma. Arch Ophthalmol. 2010;128:871–5.CrossRef Kim IK, Lane AM, Gragoudas ES. Survival in patients with presymptomatic diagnosis of metastatic uveal melanoma. Arch Ophthalmol. 2010;128:871–5.CrossRef
24.
Zurück zum Zitat Baeuerle PA, Henkel T. Function and activation of NF-κ B in the immune system. Annu Rev Immunol. 1994;12:141–79.CrossRef Baeuerle PA, Henkel T. Function and activation of NF-κ B in the immune system. Annu Rev Immunol. 1994;12:141–79.CrossRef
25.
Zurück zum Zitat Hayden MS, West AP, Ghosh S. NF-κB and the immune response. Oncogene. 2006;25:6758–80.CrossRef Hayden MS, West AP, Ghosh S. NF-κB and the immune response. Oncogene. 2006;25:6758–80.CrossRef
27.
Zurück zum Zitat Bettermann K, Vucur M, Haybaeck J, Koppe C, Janssen J, Heymann F, Weber A, Weiskirchen R, Liedtke C, Gassler N, Müller M, de Vos R, Wolf MJ, Boege Y, Seleznik GM, Zeller N, Erny D, Fuchs T, Zoller S, Cairo S, Buendia MA, Prinz M, Akira S, Tacke F, Heikenwalder M, Trautwein C, Luedde T. TAK1 suppresses a NEMO-dependent but NF-kappaB–independent pathway to liver cancer. Cancer Cell. 2010;17:481–96.CrossRef Bettermann K, Vucur M, Haybaeck J, Koppe C, Janssen J, Heymann F, Weber A, Weiskirchen R, Liedtke C, Gassler N, Müller M, de Vos R, Wolf MJ, Boege Y, Seleznik GM, Zeller N, Erny D, Fuchs T, Zoller S, Cairo S, Buendia MA, Prinz M, Akira S, Tacke F, Heikenwalder M, Trautwein C, Luedde T. TAK1 suppresses a NEMO-dependent but NF-kappaB–independent pathway to liver cancer. Cancer Cell. 2010;17:481–96.CrossRef
28.
Zurück zum Zitat Rishi P, Koundanya VV, Shields CL, Using risk factors for detection and prognostication of uveal melanoma. Indian J Ophthalmol. 2015;63110–6. Rishi P, Koundanya VV, Shields CL, Using risk factors for detection and prognostication of uveal melanoma. Indian J Ophthalmol. 2015;63110–6.
29.
Zurück zum Zitat Shields CL, Manalac J, Das C, Ferguson K, Shields JA. Choroidal melanoma: clinical features, classification, and top 10 pseudomelanomas. Curr Opin Ophthalmol. 2014;25:177–85.CrossRef Shields CL, Manalac J, Das C, Ferguson K, Shields JA. Choroidal melanoma: clinical features, classification, and top 10 pseudomelanomas. Curr Opin Ophthalmol. 2014;25:177–85.CrossRef
30.
Zurück zum Zitat Jager MJ, Ly LV, El Filali M, Madigan MC, Macrophages in uveal melanoma and in experimental ocular tumor models: friends or foes? Prog Retin Eye Res. 2011;30:129–46.CrossRef Jager MJ, Ly LV, El Filali M, Madigan MC, Macrophages in uveal melanoma and in experimental ocular tumor models: friends or foes? Prog Retin Eye Res. 2011;30:129–46.CrossRef
Metadaten
Titel
Does NEMO/IKKγ protein have a role in determining prognostic significance in uveal melanoma?
verfasst von
M. K. Singh
N. Pushker
R. Meel
K. Chodsol
S. Sen
S. Bakhshi
L. Singh
S. Kashyap
Publikationsdatum
23.05.2018
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 12/2018
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-018-1895-3

Weitere Artikel der Ausgabe 12/2018

Clinical and Translational Oncology 12/2018 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.